Multiple Myeloma
Roundtables
Treatment Sequencing in Relapsed/Refractory Multiple Myeloma
News
FDA warns of higher death risk with Pepaxto in multiple myeloma
The FDA also hinted at “a future public meeting to discuss the safety findings and explore the continued marketing of Pepaxto,” which has a price...
Conference Coverage
Personalized cancer vaccine shows early promise across tumor types
The vaccine consists of patient-specific synthetic neoantigen peptides and is given to patients in the adjuvant setting.
Feature
Cancer screening stopped by pandemic: Repercussions to come?
From the Journals
Steroids can be stopped in some older multiple myeloma patients
News
First CAR T-cell therapy for multiple myeloma: Abecma
“The results of this trial represent a true turning point in the treatment of this disease.”
Feature
FDA scrutinizes cancer therapies granted accelerated approval
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
‘Phenomenal’ results with CAR T cells in R/R multiple myeloma
Conference Coverage
Steroid complications in GVHD common, boost costs of care
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease